

29 Oct 2023 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: did Pfizer miss out on Roivant/Roche deal?; Padcev/Keytruda combo impresses in bladder cancer at ESMO; biggest upfront ever in Daiichi/Merck deal; Rybrevant at ESMO; and subcu Leqembi could open up access.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 27 October 2023, including: did [Pfizer Inc.](#) miss out on [Roivant Sciences/Roche Holding AG](#) deal?; Padcev/Keytruda combo impresses in bladder cancer at ESMO; biggest upfront ever in [Daiichi Sankyo Co., Ltd./Merck & Co., Inc.](#) deal; Rybrevant at ESMO; and subcutaneous Leqembi could open up access.

This and all our other podcasts are available on the *Citeline* channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Roivant/Roche: Did Pfizer Miss Out?](#)" - Scrip, 23 Oct, 2023.)

(Also see "[ESMO 23: Madrid Meeting Hails Padcev/Keytruda Combo As New Bladder Cancer Standard Of Care](#)" - Scrip, 23 Oct, 2023.)

(Also see "[It's Official: The Merck-Daiichi Deal Has The Biggest Upfront Ever](#)" - Scrip, 23 Oct, 2023.)

(Also see "[ESMO 2023: Will J&J's Rybrevant Be Able To Scale The Tagrisso Mountain?](#)" - Scrip, 23 Oct, 2023.)

SCRIP

CITELINE COMMERCIAL

(Also see "[CTAD 2023: Subcutaneous Leqembi Bests I.V., Could Open Access](#)" - Scrip, 25 Oct, 2023.)

[Click here to explore this interactive content online](#) 